Login to Your Account



HIF-stiffed Cerulean banks on topo to bestow

By Randy Osborne
Staff Writer

Thursday, August 18, 2016

Cerulean Pharma Inc.'s top-line phase II blowup with lead candidate CRLX101 in advanced RCC put the kibosh on the idea that targeting HIF in combination with a vascular endothelial growth factor inhibitor might work.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription